# Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid

> **NCT03622801** · — · COMPLETED · sponsor: **Bayer** · enrollment: 133331 (actual)

## Conditions studied

- Contrast Medium

## Interventions

- **DRUG:** Iopromide (Ultravist, BAY86-4877)

## Key facts

- **NCT ID:** NCT03622801
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-12
- **Primary completion:** 2019-02-14
- **Final completion:** 2019-02-14
- **Target enrollment:** 133331 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622801, "Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03622801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*